← Back to patent-cliff list
双羟萘酸帕瑞肽
Tier C — Watch / tradePasireotide Pamoate
诺华制药
Originator
2014
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：SSTR3、SSTR1、SSTR5、SSTR2
Brand：Signifor lar
Indications (approved)：肢端肥大症、库欣综合征、垂体ACTH分泌过多、巨人症
Regional status
US
批准上市
2014-12-15
EU
无进展
2008-02-11
China
批准上市
2025-04-22
Japan
批准上市
2016-09-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pasireotide Pamoate?
Approved indications include: 肢端肥大症, 库欣综合征, 垂体ACTH分泌过多, 巨人症.
When does the Pasireotide Pamoate patent expire?
No public expiry year is available for Pasireotide Pamoate yet; this page updates once verified.
How do I get a quote for Pasireotide Pamoate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24